Sen. Warren Says Trump’s CFPB Overhaul Has Cost Americans $26.5 Billion

Sen. Warren Says Trump’s CFPB Overhaul Has Cost Americans $26.5 Billion

## The architect of the consumer watchdog says rolling back credit card and overdraft protections has transferred billions from working families to the biggest banks.

---

## A $26.5 Billion Price Tag for Deregulation

On July 16, 2026, Sen. Elizabeth Warren (D-Mass.) released a report estimating that the Trump administration's overhaul of the Consumer Financial Protection Bureau (CFPB) has cost Americans up to **$26.5 billion** so far. The report, shared first with CNBC, comes as acting CFPB Director Russell Vought faces a Senate oversight hearing and the Senate weighs President Trump's nomination of Capital One executive Brian Johnson to lead the agency permanently.

"**The CFPB was created to be the cop on the beat for working families, and this administration has turned it into a doormat for the biggest banks,**" Warren said in the report.

The $26.5 billion figure breaks down into three main categories:

| Category | Cost to Consumers |

|----------|-------------------|

| **Scrapped credit-card late fee rule** | Up to $15 billion |

| **Repealed overdraft fee rule** | $7.5 billion |

| **Dropped enforcement actions and settlements** | ~$4 billion |

| **Total** | **~$26.5 billion** |

---

## The Two Rules That Cost Billions

### The $8 Credit-Card Late Fee Cap

The largest chunk of Warren's estimate—up to **$15 billion**—stems from the CFPB's decision to abandon a rule that would have capped most credit-card late fees at **$8**.

The rule was finalized under the Biden administration in March 2024 and was projected to reduce the average late fee from $32 to $8, saving the roughly **45 million Americans** who incur late fees each year an estimated **$10 billion annually**. The CFPB under Vought withdrew the rule in February 2025, allowing card issuers to continue charging fees that averaged **$34 per incident**.

### The Overdraft Fee Rule

Another **$7.5 billion** comes from the repeal of the CFPB's overdraft fee rule, which would have limited many banks to charging **$5** for overdrafts.

The rule targeted what the CFPB described as a **$9 billion annual revenue stream** for large banks. The agency estimated that **23 million households** pay overdraft fees each year, with the heaviest users incurring more than **$300 annually**.

---

## Dropped Enforcement Actions Add $4 Billion

The remaining **roughly $4 billion** in consumer costs comes from the CFPB's decision to drop more than **three dozen enforcement actions and consent orders**.

The dropped actions included cases targeting **JPMorgan Chase, Bank of America, and Wells Fargo** over alleged consumer abuses. Some of these cases were set to send payments directly to consumers. The report estimates those dropped actions represent roughly **$4 billion in potential consumer relief that never reached affected households**.

---

## The Broader CFPB Overhaul

Since taking office, the Trump administration has pursued a sweeping overhaul of the CFPB:

- **Slashed staffing** at the agency

- **Dropped or narrowed dozens** of enforcement cases

- **Rolled back Biden-era rules** on credit cards, overdrafts, and other consumer protections

- **Removed 15 years of consumer data** from the CFPB website, according to an allegation

- **Changed the consumer complaint portal** to discourage complaints, critics say

The administration has defended the moves as necessary to rein in what it views as an overreaching regulator and refocus the agency on its core mission.

---

## The Political Battle

The report lands at a critical moment. Acting Director Russell Vought faces a Senate oversight hearing Thursday over the agency's sweeping changes. At the same time, the Senate is weighing President Trump's nomination of **Brian Johnson**, a former CFPB deputy director turned Capital One executive, to lead the bureau permanently.

Republicans have defended the moves as necessary to rein in what they view as an overreaching regulator. The White House and CFPB did not immediately respond to requests for comment.

Democrats, led by Warren—who **conceived and helped set up the agency** after the 2008 financial crisis—have argued that the Trump administration has crippled a key consumer financial watchdog and exposed Americans to unfair or deceptive industry practices.

---

## What This Means for American Consumers

### Credit Card Holders

The decision to scrap the $8 late-fee cap means the roughly **45 million Americans** who incur late fees each year continue to pay an average of **$34 per incident** instead of the $8 that would have been allowed under the rule. That's a difference of **$26 per late payment**—money that stays in the pockets of card issuers rather than consumers.

### Bank Customers

The repeal of the overdraft fee rule means the **23 million households** that pay overdraft fees each year continue to face charges that average **$35 per incident** instead of the $5 that would have been allowed. The heaviest users incur more than **$300 annually**.

### The Bigger Picture

Warren's report argues that the CFPB overhaul represents a fundamental shift in who the agency serves. "**The CFPB was created to be the cop on the beat for working families, and this administration has turned it into a doormat for the biggest banks,**" she said.

The report also notes that a reversal of the current policy direction could threaten billions in fee revenue for large U.S. consumer banks including **JPMorgan Chase, Bank of America, and Citigroup**.

---

## Frequently Asked Questions

### Q: What is the CFPB?

The Consumer Financial Protection Bureau is a U.S. government agency created after the 2008 financial crisis to protect consumers from unfair, deceptive, or abusive practices in the financial marketplace. Sen. Elizabeth Warren conceived and helped set up the agency.

### Q: How did the CFPB overhaul cost Americans $26.5 billion?

According to Warren's report, the cost breaks down as follows: up to $15 billion from scrapping the credit-card late fee cap, $7.5 billion from repealing the overdraft fee rule, and roughly $4 billion from dropped enforcement actions and settlements.

### Q: What was the credit-card late fee rule?

The rule, finalized in March 2024, would have capped most credit-card late fees at $8. The CFPB estimated it would save roughly 45 million Americans about $10 billion annually. The Trump administration withdrew the rule in February 2025.

### Q: What was the overdraft fee rule?

The rule would have limited many banks to charging $5 for overdrafts. The CFPB estimated that 23 million households pay overdraft fees each year, with the heaviest users paying more than $300 annually. The rule was repealed under the Trump administration.

### Q: Who is Russell Vought?

Russell Vought is the acting director of the CFPB under the Trump administration. He has overseen the agency's sweeping overhaul, including rolling back rules on credit-card late fees and overdraft charges, dropping enforcement actions, and changing the consumer complaint portal.

### Q: Who is Brian Johnson?

Brian Johnson is a former CFPB deputy director turned Capital One executive whom President Trump has nominated to lead the CFPB permanently. The Senate is currently weighing his nomination.

### Q: What do Republicans say about the CFPB overhaul?

Republicans have defended the moves as necessary to rein in what they view as an overreaching regulator and refocus the agency on its core mission.

---

## Conclusion: A Defining Battle Over Consumer Protection

Sen. Warren's $26.5 billion estimate is more than just a number. It's a political weapon in a defining battle over the future of consumer financial protection in America.

The CFPB was created after the 2008 financial crisis to be "the cop on the beat for working families." Under the Trump administration, Warren argues, it has become "a doormat for the biggest banks". The administration argues it is simply reining in an overreaching regulator.

The clash comes as the Senate weighs whether to confirm Brian Johnson, a former CFPB deputy director turned Capital One executive, to lead the agency permanently. The outcome of that confirmation fight—and the broader debate over the CFPB's future—will determine whether American consumers continue to pay billions in fees that might otherwise have been capped or eliminated.

For the **45 million Americans** who incur credit-card late fees each year and the **23 million households** that pay overdraft fees, the stakes could hardly be higher.

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. The estimates and figures cited in this article are from Sen. Elizabeth Warren's report and have not been independently verified. The White House and CFPB did not respond to requests for comment on the report. You should consult with qualified professionals before making any decisions based on this information.

---

*Published: July 16, 2026*

--Read more-

**Tags:** Elizabeth Warren, CFPB, Consumer Financial Protection Bureau, Trump administration, Russell Vought, Brian Johnson, credit card late fees, overdraft fees, consumer protection, banking regulation, financial regulation, consumer costs, Senate Banking Committee, JPMorgan Chase, Bank of America, Citigroup, Wells Fargo, Dodd-Frank, consumer finance

Lilly's $3.8 Billion Psychedelic Bet: Why the Weight-Loss King Just Bought a Depression Drug Startup

 Lilly's $3.8 Billion Psychedelic Bet: Why the Weight-Loss King Just Bought a Depression Drug Startup

## The maker of Mounjaro and Zepbound is making its biggest bet yet on mental health—and it could change how we treat depression forever.

---

### Introduction: From Weight Loss to Mind Expansion

Eli Lilly has a problem that most drugmakers would envy. Its GLP-1 drugs, Mounjaro and Zepbound, have made the company the most valuable healthcare firm in the world. But the patents on these blockbusters won't last forever. And Lilly knows it needs to find the next big thing.

On July 16, 2026, the company made its most surprising move yet: it agreed to acquire AtaiBeckley Inc., a clinical-stage biotech developing psychedelic-based mental health treatments, for up to **$3.8 billion**.

The deal marks Lilly's first major foray into the once-fringe field of psychedelic medicine. It also signals that big pharma is finally taking psychedelics seriously as a treatment for some of the most challenging mental health conditions—especially treatment-resistant depression (TRD), which affects millions of people who don't respond to existing antidepressants.

AtaiBeckley shares jumped more than 30% in premarket trading following the announcement. Compass Pathways rose 7.4% and GH Research surged 18.9%, as investors bet that Lilly's move would validate the entire sector.

"The deal would provide differentiated exposure in psychiatry and reinforce the company's broader effort to diversify beyond its cornerstone cardiometabolic franchise," BMO Capital Markets analysts wrote in a note to investors.

---

### The Deal: $2.8 Billion Upfront, $1 Billion in Milestones

Here's how the numbers break down:

| Component | Amount |

|-----------|--------|

| **Upfront cash** | $2.8 billion ($6.75/share) |

| **Contingent Value Rights (CVRs)** | Up to $1.0 billion ($2.50/share) |

| **Total potential value** | **$3.8 billion** |

The upfront price represents a **40% premium** to AtaiBeckley's 30-day volume-weighted average trading price. The Contingent Value Rights are tied to specific development and regulatory milestones for AtaiBeckley's two lead programs: **BPL-003** and **VLS-01**.

- **$1 per share** is tied to the start of Phase 3 trials of VLS-01

- **$1 per share** is tied to U.S. regulatory approval and rescheduling of VLS-01

- **$0.50 per share** is tied to approval and rescheduling of BPL-003

The deal is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals. The boards of both companies have already signed off.

---

### The Science: Why Psychedelics for Depression?

The conventional antidepressants on the market today—SSRIs like Prozac and Zoloft—work by altering neurotransmitter levels in the brain. They help many people, but they don't work for everyone. And even when they do, they can take weeks or months to kick in.

AtaiBeckley's approach is fundamentally different.

Emerging research suggests that treatment-resistant depression and other serious mental health conditions may involve a **loss of synaptic plasticity**—the brain's ability to form and strengthen connections in regions critical to mood regulation. AtaiBeckley's therapies are designed to **restore synaptic connectivity** and promote the growth of new neural connections, offering a "distinct mechanism from conventional antidepressants," according to Lilly's statement.

### BPL-003: The Lead Asset

The crown jewel of the acquisition is **BPL-003 (mebufotenin benzoate)** , a synthetic form of **5-MeO-DMT** administered intranasally. (5-MeO-DMT is a psychedelic substance found in some plants and animals that stimulates the serotonin system that regulates mood.)

In a Phase 2b study, BPL-003 demonstrated "rapid and durable reductions in depressive symptoms" following an in-clinic visit lasting about two hours. The effects persisted for months. Patients were typically ready for discharge after 90 minutes.

That's a significant advantage over existing treatment options:

| Treatment | Administration | Monitoring Time |

|-----------|---------------|-----------------|

| **J&J's Spravato (esketamine)** | Nasal spray | 2 hours |

| **BPL-003** | Nasal spray | ~90 minutes |

The shorter monitoring time positions BPL-003 to fit into the treatment infrastructure already established for Spravato. BPL-003 has also been granted **Breakthrough Therapy Designation** by the FDA.

### The Pipeline Beyond BPL-003

AtaiBeckley is also developing:

- **VLS-01**: A DMT buccal (cheek) film for treatment-resistant depression

- **EMP-01**: An (R)-MDMA HCI therapy for social anxiety disorder

The company is "advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a discovery pipeline of next-generation compounds".

---

### The Strategic Rationale: Why Lilly Is Betting Big

#### Diversifying Beyond GLP-1

Lilly's GLP-1 drugs—Mounjaro and Zepbound—have been cash machines. But the company knows it can't rely on them forever. Before the AtaiBeckley deal, Lilly had already pledged more than **$10 billion in upfront payments** across eight separate acquisitions in 2026.

The company has "deliberately targeted later stage and therefore more expensive deals than it has historically pursued as it settles into its status as the world's most valuable healthcare company".

#### The Trump Administration Tailwind

The deal also comes at a moment of unusual regulatory openness. The Trump administration has "prioritized development of psychedelic-based treatments for mental health conditions, including depression and post-traumatic stress disorder".

#### The J&J Challenge

Lilly is positioning itself to challenge Johnson & Johnson's dominance in the treatment-resistant depression market. J&J's **Spravato (esketamine)** is one of only two FDA-approved TRD drugs.

AtaiBeckley CEO Srinivas Rao has said the company "essentially taken the lessons from earlier interventional approaches, including Spravato, and designed treatments that retain or possibly even improve upon efficacy while dramatically reducing complexity".

#### The GH Research Read-Through

RBC Capital analysts noted that GH Research represents "the most direct and compelling read-through" to the acquisition, given the near-identical mechanism of its lead asset, GH001, to AtaiBeckley's BPL-003—both based on 5-MeO-DMT and targeting TRD.

Analyst Brian Abrahams noted that Lilly's willingness to pay a premium for AtaiBeckley "would set a floor for GHRS shares and also further validate the class as well as position the company as a compelling opportunity for other strategics".

---

### The Human Element: What This Means for Patients

#### For the 30% Who Don't Respond to Antidepressants

About **one-third of patients with depression don't respond to conventional antidepressants**. For them, the current options are limited: electroconvulsive therapy, ketamine infusions, or simply living with a condition that doesn't respond to treatment.

BPL-003 offers something different: a single in-clinic treatment that could provide relief for months. It's not a daily pill. It's not a weekly injection. It's a two-hour visit that could change the trajectory of someone's life.

#### For the Patients Who've Given Up

The most devastating statistic in mental health is this: **many patients stop seeking treatment after multiple failures**. They assume nothing will work. They assume they're beyond help.

Lilly's bet on psychedelics sends a different message: that new approaches are coming. That there's still hope.

#### The "Psychedelic Renaissance" Goes Mainstream

For years, psychedelic medicine was dismissed as a fringe pursuit. But the science has been building for decades. And now, with Lilly's $3.8 billion bet, the psychedelic renaissance has officially gone mainstream.

As one analyst put it, the deal "further validate[s] the class" of psychedelic-based mental health treatments.

---

### Frequently Asked Questions

**Q: How much is Lilly paying for AtaiBeckley?**

A: Lilly is paying **$2.8 billion upfront** ($6.75 per share), with up to an additional **$1.0 billion** ($2.50 per share) tied to development and regulatory milestones. The total potential value is **$3.8 billion**.

**Q: What is BPL-003?**

A: BPL-003 is a synthetic form of **5-MeO-DMT** administered intranasally. It's being developed for treatment-resistant depression and has shown rapid and durable reductions in depressive symptoms in clinical trials.

**Q: Why is Lilly buying a psychedelic drugmaker?**

A: Lilly is diversifying beyond its GLP-1 franchise, which won't generate blockbuster revenue forever. The company has been on an acquisition spree, spending more than **$10 billion upfront** on eight deals in 2026.

**Q: When will the deal close?**

A: The deal is expected to close in the **third quarter of 2026**, subject to shareholder and regulatory approvals.

**Q: Does this mean psychedelics are legal now?**

A: No. The drugs are still investigational and require FDA approval. However, the Trump administration has prioritized development of psychedelic-based treatments.

**Q: How does BPL-003 compare to existing treatments?**

A: BPL-003 works through a different mechanism than conventional antidepressants. It's designed to **restore synaptic connectivity** and promote neural growth. In clinical trials, patients were ready for discharge after about 90 minutes—shorter than the two-hour monitoring required for J&J's Spravato.

**Q: What else is in AtaiBeckley's pipeline?**

A: AtaiBeckley is also developing **VLS-01** (a DMT buccal film for TRD) and **EMP-01** (an MDMA-based therapy for social anxiety disorder).

**Q: Will this affect Lilly's stock price?**

A: The acquisition is expected to be accretive to Lilly's long-term growth, but the upfront cost will impact earnings in the near term. Lilly shares were trading slightly lower on the news.

---

### Conclusion: A $3.8 Billion Bet on the Future of Mental Health

Eli Lilly's acquisition of AtaiBeckley is more than just another pharma deal. It's a signal that the psychedelic renaissance has arrived—and that the world's biggest drugmakers are finally taking mental health as seriously as they take diabetes and obesity.

The science is compelling. The regulatory environment is opening up. And the need is urgent: millions of people with treatment-resistant depression are running out of options.

Lilly is betting that BPL-003 and its pipeline of "rapid-acting neuroplastogens" can offer something different: not just symptom management, but **real biological repair**. Not just a daily pill, but a treatment that could provide relief for months after a single visit.

As AtaiBeckley CEO Srinivas Rao put it, the company has designed treatments that "retain or possibly even improve upon efficacy while dramatically reducing complexity".

For the millions of patients who have tried everything and still suffer, that's not just a good deal. It's a lifeline.

--Read more from moon light-

### Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or medical advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. The proposed acquisition is subject to shareholder and regulatory approvals and may not be completed. All investments carry risk, including the potential loss of principal. Psychedelic-based treatments are investigational and have not been approved by the FDA for commercial use. You should consult with a qualified healthcare provider before making any decisions about medical treatments, and with a financial advisor before making any investment decisions.

---

*Published: July 16, 2026*

--Read more-

**Tags:** Eli Lilly, AtaiBeckley, psychedelic drugs, treatment-resistant depression, mental health, BPL-003, 5-MeO-DMT, psychedelic medicine, pharma M&A, Lilly acquisition, neuroscience, depression treatment, GLP-1 diversification, psychedelic stocks, biotech M&A

Gas Prices Masked a Resilient Consumer in June: What the 0.2% Retail Sales Rise Really Means

 

Gas Prices Masked a Resilient Consumer in June: What the 0.2% Retail Sales Rise Really Means

**Headline numbers were held back by a 5.3% plunge at the pump, but core retail sales surged 0.5%. Here's the real story behind the data—and why the respite at the pump may already be over.**

---

## Introduction: The Tale of Two Retail Sales Reports

On the surface, the June retail sales report looked like a slowdown. The Commerce Department reported a modest 0.2% month-over-month increase, a notable deceleration from May's revised 1.0% jump. Headline sales came in at $768.6 billion, exactly in line with economists' expectations.

But beneath that modest headline lies a much more interesting story.

Excluding gasoline stations—where receipts plunged 5.3% in the sharpest monthly decline since 2022—retail sales rose a robust 0.7%. And "control-group" sales, which feed directly into the government's calculation of GDP, rose 0.5%. For context, the control group excludes food services, auto dealers, building materials stores, and gasoline stations, providing the cleanest read on underlying consumer spending.

The numbers are clear: **headline weakness was almost entirely a gas-station story**. And that distinction matters enormously for how we interpret the health of the American consumer.

---

## The Gasoline Factor: A 50-Cent Tax Cut

The primary drag on headline retail sales was a dramatic drop in gasoline prices. The national average price at the pump fell roughly **50 cents a gallon** in June, from $4.61 in May to $4.18. This decline was driven by a brief, shaky ceasefire between the United States and Iran, which sent oil prices temporarily lower.

The result: gasoline station receipts fell 5.3% in June. That's the sharpest monthly decline since 2022.

"Lower gasoline prices mean June retail sales understate the strength of demand," Bloomberg Economics' Eliza Winger said in a note. "The roughly 50-cent decline in gasoline prices acted like a tax cut for consumers, freeing up cash for other purchases," added Elizabeth Renter, senior economist at NerdWallet.

In other words: consumers didn't stop spending. They just spent less at the pump—and redirected those savings elsewhere.

---

## Where the Money Went: A Resilient Consumer in Action

When you strip away the gas-station noise, a picture of remarkable consumer resilience emerges.

**Online Sales: +1.9%**

Nonstore retailers jumped 1.9%, the biggest increase in nearly a year. This was fueled in large part by Amazon's Prime Day event, which ran from June 23 through June 26. Adobe Inc. reported that online spending across all retailers was up during Prime Day compared with last year's event.

**Motor Vehicles and Parts: Strongest Gain Since July 2025**

Outlays at auto dealers jumped nearly 2% in June. Buying a car is a big financial decision that tends to reflect confidence in the economy. The jump in auto sales suggests that despite high prices and interest rates, consumers are still willing to make major purchases.

**Sporting Goods and Hobby Stores: +1.3%**

Business at sporting goods, hobby, musical instrument, and book stores was up 1.3%, helped by spending around the FIFA World Cup. The tournament, co-hosted by the U.S., Canada, and Mexico, provided a boost to discretionary categories.

**Electronics and Appliance Stores: Also Rose**

Other discretionary categories, such as electronic and appliance stores, also posted gains. This suggests that consumers are still willing to spend on big-ticket items when they have the means.

**Restaurants and Bars: Edged Up**

The lone services category in the retail report—restaurants and bars—edged up 0.1%. While modest, this represents continued spending on experiences despite economic uncertainty.

---

## The Core Story: Control-Group Sales Rose 0.5%

For economists, the most important number in the report is the "control-group" sales figure—the measure that feeds into the government's calculation of goods spending for GDP.

The control group rose **0.5% in June**, marking the sixth consecutive increase. This was in line with expectations and followed an upwardly revised 0.8% rise in May.

**What the control group includes:**

- General merchandise stores

- Clothing and accessories stores

- Furniture and home furnishing stores

- Electronics and appliance stores

- Sporting goods, hobby, and book stores

- Nonstore retailers (e-commerce)

- Food and beverage stores

**What it excludes:**

- Motor vehicles and parts

- Gasoline stations

- Building materials

- Food services and drinking places

By excluding the most volatile categories, the control group provides the cleanest read on underlying consumer demand. And at 0.5%, it suggests that **core consumer spending remains robust**.

---

## The Income Divide: A K-Shaped Recovery

The retail sales report also highlighted the growing divergence between higher- and lower-income households—a trend that has been building for years.

**Higher-income households continue to drive spending.** They've seen their wealth boosted by a stock market rally, and they're less affected by inflation at the grocery store and the pump.

**Lower-income households are trading down.** Bank of America card data showed that lower-income families have traded down "five times faster at discount apparel stores than higher-income households so far in 2026". They're increasingly looking to general merchandise stores for deals and discounts.

"Price-conscious consumers are increasingly looking to general merchandise stores for deals and discounts," a Bank of America Institute report noted.

**Spending picked up across income groups in June.** Bank of America card data showed spending picked up steam across income groups in June, with lower-income households in particular benefiting from reduced prices at the pump. This suggests that the temporary ceasefire provided a meaningful boost to lower-income families who spend a larger share of their income on gasoline.

---

## The Economic Context: A Resilient but Cautious Consumer

The June retail sales report arrives amid a complex economic backdrop:

**Inflation is cooling—but prices remain high.** Consumer prices dropped 0.4% from May to June, the largest monthly drop in four years. The annual inflation rate declined to 3.5%, down from 4.2% in May. But prices are still more than 25% higher than five years ago. As Ryan Sweet, chief global economist at Oxford Economics, put it: "A lower inflation rate doesn't mean prices are falling — it just means they're rising more slowly".

**The labor market is cooling but remains solid.** Nonfarm payrolls have averaged 177,000 per month over the past three months, above the roughly 100,000 breakeven rate. And applications for unemployment benefits fell last week to 208,000, the lowest level since May.

**Consumer confidence is improving—but still negative.** A report from the Conference Board showed that Americans' attitudes toward the economy improved slightly in June as gas prices declined, but their outlook is still mostly negative by historical standards.

**The Iran ceasefire was short-lived.** The respite in gas prices may prove temporary. The U.S. and Iran have renewed attacks on one another, driving up oil prices and once again disrupting shipping through the Strait of Hormuz.

---

## What This Means for the Federal Reserve

The retail sales data provides some support for the view that consumer spending can hold up even as the labor market shows signs of cooling. This gives the Federal Reserve room to maintain its current stance while it assesses whether disinflation can sustain.

Fed Governor Chris Waller said this week the central bank needs to see the disinflationary trend hold over several months before calling off further tightening. Markets currently price one more rate increase this year, with the next decision due July 29.

---

## The Human Element: What This Means for You

**For the average American consumer**, the June report is a mixed bag. If you drive a lot, you probably noticed the drop in gas prices—and you may have used those savings to buy something else. But if you're in a lower-income household, you're still feeling the pinch of higher prices for everyday goods, even if the rate of inflation is slowing.

Sarah Williamson, a 27-year-old software support engineer in Raleigh, North Carolina, told the Associated Press that she feels financially secure given her stable job, but increasing costs of food and gas are making her pull back on frivolous spending. "I shop less overall as a hobby," she said. She's buying whole cantaloupes instead of pre-cut fruit to save money, and she's careful about buying clothing for herself.

**For small business owners**, the data offers a cautiously optimistic picture. Brian Reynolds, CEO of Just For Teens, a skincare line aimed at preteens and teens, noted that his low-price products—including $5 pimple patches—are "in the sweet spot of retailing right now". His brand is expanding to 10,000 Dollar General stores from about 4,000 late last year.

**For investors**, the retail sales report confirms that the consumer remains resilient—but also that the recovery is uneven. Higher-income households continue to drive spending, while lower-income families are trading down to discount stores. The Fed will be watching closely to see if the disinflationary trend holds.

---

## The Cloud on the Horizon: The Iran Conflict Resumes

The most significant risk to the consumer outlook is the resumption of the Iran conflict. The temporary ceasefire that drove gas prices lower in June has collapsed, and the U.S. and Iran have renewed attacks on one another.

President Donald Trump announced a new blockade in the Strait of Hormuz, a key shipping route for about one-fifth of the world's oil. The increase threatens to unravel at least some of the progress that occurred last month.

If gas prices rise again—and they already are—the respite that consumers enjoyed in June could be short-lived. For lower-income households in particular, a return to $4.61-per-gallon gasoline would be a significant blow to their spending power.

---

## Frequently Asked Questions

### Q: What were the headline retail sales numbers for June 2026?

A: Retail sales rose 0.2% month-over-month to $768.6 billion, in line with economists' expectations. This followed an upwardly revised 1.0% increase in May. Year-over-year, sales were up 6.7%.

### Q: Why did retail sales growth slow so much from May?

A: The slowdown was largely driven by a sharp 5.3% drop in gasoline station receipts, as gas prices fell about 50 cents a gallon in June. Excluding gas stations, retail sales rose a robust 0.7%.

### Q: What is the "control group" and why does it matter?

A: The control group is a measure of core retail sales that excludes motor vehicles, gasoline stations, building materials, and food services. It feeds directly into the government's calculation of GDP and provides the cleanest read on underlying consumer spending. It rose 0.5% in June.

### Q: Did consumers actually slow their spending in June?

A: Not really. While headline growth slowed, the underlying data shows that consumers remained resilient. Online sales jumped 1.9%, auto sales posted their strongest gain since July 2025, and sporting goods stores rose 1.3%. The headline weakness was almost entirely a gas-station story.

### Q: Why did gas prices fall in June?

A: Gas prices fell because of a temporary ceasefire between the U.S. and Iran, which sent oil prices lower. The national average pump price dropped roughly 50 cents a gallon.

### Q: Will gas prices stay low?

A: Probably not. The ceasefire has collapsed, and the U.S. and Iran have renewed attacks on one another. Oil prices are rising again, which will likely push gasoline prices higher in the coming weeks.

### Q: What does this mean for the Federal Reserve?

A: The data provides support for the view that consumer spending can hold up even as the labor market cools. This gives the Fed room to maintain its current stance while assessing whether disinflation can sustain. Markets currently price one more rate increase this year.

---

## Conclusion: A Resilient Consumer—for Now

The June retail sales report tells a story of a consumer that is resilient but cautious. Headline growth of 0.2% masked a 5.3% plunge at the pump and a robust 0.5% rise in core spending. Cheaper gas freed up cash for other purchases, and consumers responded by buying more cars, more online goods, and more sporting goods.

But the respite at the pump may already be over. The ceasefire has collapsed, and gas prices are rising again. For lower-income households in particular, the return of higher energy costs could be a significant blow to their spending power.

The economy continues to grow, layoffs are low, and businesses are investing heavily in new technologies. As one MarketWatch analysis put it: "Americans are spending more than enough to keep the economy out of danger".

But the uncertainty from the Middle East war, high inflation, and the fading benefits of generous government tax refunds suggest that the consumer's resilience will continue to be tested.

👎

Read more

The $315 Pill That Could Save Your Heart: FDA Approves First Oral Drug That Slashes Cholesterol to "Impossibly Low" Levels

 

The $315 Pill That Could Save Your Heart: FDA Approves First Oral Drug That Slashes Cholesterol to "Impossibly Low" Levels

**For the first time in history, patients can now pop a daily pill that lowers "bad" LDL cholesterol by up to 60%—matching the power of expensive injectables at half the cost. The era of the statin may finally be over.**

---

## Introduction: The End of an Era

For nearly 40 years, statins have been the undisputed gold standard for cholesterol management. Since Merck discovered lovastatin—the first statin to gain FDA approval, back in 1987—these drugs have saved countless lives by lowering LDL cholesterol and reducing the risk of heart attacks and strokes. But even the most powerful statins have their limits. They block an enzyme the liver uses to make cholesterol, but they can only take patients so far. For millions of Americans, statins alone aren't enough to reach the aggressive new LDL targets recommended by the American Heart Association and the American College of Cardiology.

That all changed on July 16, 2026.

The U.S. Food and Drug Administration approved **Lipfendra (enlicitide)** , the first-ever oral PCSK9 inhibitor, for adults with high cholesterol. It's a once-daily pill that can slash LDL cholesterol by up to 60%—far beyond what statins can achieve. And it's a fraction of the cost of existing injectable PCSK9 inhibitors, which have been available for years but never achieved widespread adoption due to high prices and the inconvenience of injections.

**For the first time, patients can get injectable-level cholesterol reduction from a pill they can take at home.**

---

## The Numbers That Matter: A 60% Plunge in "Bad" Cholesterol

To understand why this approval is such a big deal, you have to understand the numbers.

Most adults have LDL cholesterol levels above 100 mg/dL. That's considered borderline high. But cardiologists now recommend that patients at risk of heart attack or stroke aim for LDL levels **below 70**—and for people at high risk, the target is **below 55**. Statins can get some patients there, but not all.

Lipfendra can.

In two phase 3 clinical trials involving 3,207 adults with severe hypercholesterolemia—including those with an inherited condition called heterozygous familial hypercholesterolemia (HeFH)—the results were striking:

| Trial Population | Baseline LDL | LDL Reduction vs. Placebo | Target Achievement |

|------------------|--------------|---------------------------|-------------------|

| High-risk/ASCVD patients | 96 mg/dL | **-56%** | 70.3% achieved LDL < 70 mg/dL |

| HeFH patients | 119 mg/dL | **-59%** | 67.5% achieved LDL < 55 mg/dL |

In plain English: **Lipfendra reduced "bad" cholesterol by 56% to 59% compared to placebo**. In the high-risk trial, more than **70% of patients** achieved an LDL level below 70 mg/dL, and nearly 68% got below 55 mg/dL—the new aggressive targets for high-risk patients.

The drug also lowered other dangerous lipids, including non-HDL cholesterol by 53.4%, apolipoprotein B by 50.3%, and lipoprotein(a) by 28.2%. These are all markers that cardiologists use to assess cardiovascular risk.

**The bottom line:** Lipfendra can take patients to cholesterol levels that were previously only achievable with expensive, inconvenient injectable drugs—or not achievable at all.

---

## How It Works: The PCSK9 Pathway

To understand why Lipfendra is such a breakthrough, you need to understand the biology.

Your liver produces a protein called **PCSK9** that essentially destroys the LDL receptors on the surface of your liver cells. Those receptors are responsible for clearing "bad" cholesterol from your blood. The more PCSK9 you have, the fewer receptors you have, and the more cholesterol stays in your bloodstream.

Lipfendra is a **macrocyclic peptide**—a molecule designed to bind to circulating PCSK9 and block its interaction with the LDL receptor. By blocking PCSK9, it prevents the destruction of LDL receptors, allowing more receptors to remain on the surface of liver cells to clear LDL-C from the blood.

In other words: **Lipfendra unblocks your body's natural cholesterol-clearing machinery.**

This is the same mechanism used by injectable PCSK9 inhibitors like Amgen's Repatha and Regeneron's Praluent, which have been available for a decade. But those drugs require subcutaneous injections—often monthly or biweekly—and have list prices that can exceed $600 per month. Lipfendra is a pill you take once a day, and it costs **$315 for a 30-day supply**.

**The "same known pathway" as the injectables, but in a pill form that costs half as much**.

---

## The Price Point: A Game-Changer for Access

One of the biggest barriers to PCSK9 inhibitors has been cost. Injectable PCSK9 drugs like Repatha and Praluent have list prices that can exceed $600 per month, and while insurance coverage has improved, many patients still face high copays or prior authorization hurdles.

Lipfendra's list price is **$315 per month**—roughly half that of the injectable alternatives. It will also be available through the direct-to-patient TrumpRx program, which could further reduce out-of-pocket costs for eligible patients.

Merck's strategy is clear: **price it lower than the competition to drive adoption and capture market share.** Analysts expect Lipfendra to reach peak annual sales of **$5 billion**, and some have suggested "tens of billions of dollars" in potential.

For patients who have been taking injectable PCSK9 inhibitors, the switch could mean significant cost savings and greater convenience. For patients who couldn't afford the injectables, Lipfendra could be the first time they can access this level of cholesterol reduction.

---

## The Human Element: What This Means for Patients

### For the Patient Who Can't Tolerate Statins

Up to 10% of patients experience muscle pain or other side effects from statins. For them, the options have been limited. Ezetimibe and bempedoic acid can help, but they only lower LDL by about 20%. Lipfendra offers a completely different mechanism—and it can be used in patients who are already taking statins, or potentially as an alternative for those who can't tolerate them.

### For the Patient with Familial Hypercholesterolemia

HeFH is an inherited condition that causes extremely high cholesterol levels from birth. Patients with HeFH often have LDL levels above 190 mg/dL and are at dramatically increased risk of early heart attacks. In the HeFH trial, patients had an average baseline LDL of 119 mg/dL—even while already taking maximally tolerated statin therapy. Lipfendra lowered their LDL by 59%.

### For the Patient at High Risk

For patients who have already had a heart attack or stroke—or who are at high risk for one—the new AHA/ACC guidelines recommend LDL targets below 55 mg/dL. In the high-risk trial, 67.5% of Lipfendra-treated patients achieved that target, compared to just 1.2% of patients on placebo.

### The Human Emotions Behind the Headlines

- **The patient**: You've been on statins for years. Your LDL is still above 100. Your doctor has been talking about injectable PCSK9 inhibitors, but they're expensive and you hate needles. Now there's a pill.

- **The cardiologist**: You've been waiting for this moment. You've seen patients struggle with injectables, miss doses, or simply give up. A pill changes everything.

- **The pharmacist**: You're about to see a flood of new prescriptions. You need to know the fasting requirements and the interactions.

- **The primary care doctor**: You've been managing your patients' cholesterol for decades. This is the biggest change in cholesterol management since statins.

---

## The Catch: Fasting, Food Interactions, and Side Effects

No drug is perfect, and Lipfendra has its limitations.

**The fasting requirement is strict.** Patients must take the tablet in the morning on an empty stomach and avoid food or beverages other than water for **30 minutes after dosing**. It also requires an **eight-hour fast before it can be taken**. This challenging regime raises potential questions about patient compliance.

**The side effects are mild.** In the HeFH trial, the most common adverse events occurring more frequently with Lipfendra than placebo were **diarrhea and dizziness**. Adverse event rates were similar between treatment groups overall, and discontinuation rates were comparable between Lipfendra and placebo.

**The big unknown:** While the trials showed that Lipfendra provides significant reductions in atherogenic lipoproteins, **it is not yet known if the treatment can reduce the risk of cardiovascular morbidity and mortality**. Merck is conducting ongoing trials to determine whether the drug can actually prevent heart attacks and strokes. This is a critical distinction: lowering cholesterol is a surrogate endpoint; preventing cardiovascular events is the real goal.

---

## The Bigger Picture: What This Means for Merck

For Merck, Lipfendra is more than just a new drug—it's a **strategic lifeline**.

The company's blockbuster cancer treatment Keytruda is set to lose key patent protections starting in 2028, exposing the company to competition from biosimilar versions. Keytruda generated $31.7 billion—**55% of Merck's total revenue**—last year. The company desperately needs new revenue streams to fill the gap.

Lipfendra is expected to reach peak annual sales of **$5 billion**, and some analysts have suggested "tens of billions of dollars" in potential. Merck's stock was up **3%** on the approval news.

The company also received a **Priority Review** designation for Lipfendra, which is intended to slash review periods for drugs that are critical to public health or national security. The FDA Commissioner's National Priority Voucher program approved the drug in just 1-2 months, rather than the standard 6-12 months.

**Lipfendra is Merck's best hope for replacing Keytruda's revenue.** And with a pill that's cheaper, more convenient, and just as effective as injectable alternatives, it has the potential to reshape the entire cholesterol management market.

---

## What This Means for the Cholesterol Drug Market

### The Injectable PCSK9 Market Is in Trouble

Injectable PCSK9 inhibitors like Repatha and Praluent have been on the market for a decade, but they've never achieved the blockbuster sales that analysts once predicted. The reasons are clear: high prices, insurance hurdles, and patient reluctance to use injectable drugs.

Lipfendra addresses all three problems. It's cheaper (half the price), it's a pill (no needles), and it's available through a direct-to-patient program (TrumpRx). **For patients who have been taking injectable PCSK9 inhibitors, the switch to a cheaper, more convenient pill is almost inevitable.**

### The Statin Market Is Under Pressure

Statins have been the standard of care for cholesterol management for nearly 40 years. They're cheap, generic, and effective. But they can only lower LDL by about 30-50% at maximum doses. For patients who need to get below 70 or 55 mg/dL, statins alone often aren't enough.

Lipfendra is a **complement**, not a replacement, for statins. It's approved for use in patients who are **already taking maximally tolerated statin therapy**. But it could also be used as an alternative for patients who can't tolerate statins—and that could put pressure on the statin market over time.

### The Oral PCSK9 Era Has Arrived

Lipfendra is the first oral PCSK9 inhibitor, but it won't be the last. Other companies are developing oral PCSK9 candidates, and Merck's approval validates the entire class. **Within five years, the PCSK9 market could shift from injectables to pills.**

---

## Frequently Asked Questions

### Q: What is Lipfendra?

Lipfendra (enlicitide) is the first oral PCSK9 inhibitor approved by the FDA. It's a once-daily pill that lowers "bad" LDL cholesterol by up to 60%.

### Q: How does it work?

Lipfendra blocks the PCSK9 protein, which normally destroys LDL receptors on liver cells. By blocking PCSK9, it allows more LDL receptors to remain on the surface of liver cells to clear cholesterol from the blood.

### Q: How much does it cost?

Lipfendra has a list price of **$315 for a 30-day supply**—roughly half the cost of injectable PCSK9 inhibitors.

### Q: Who is it for?

Lipfendra is approved for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), who are already taking maximally tolerated statin therapy.

### Q: How effective is it?

In clinical trials, Lipfendra lowered LDL cholesterol by **56% to 59%** compared to placebo. More than 70% of patients achieved LDL levels below 70 mg/dL.

### Q: Does it have side effects?

The most common side effects are **diarrhea and dizziness**. Adverse event rates were similar between Lipfendra and placebo, and discontinuation rates were comparable.

### Q: Does it require fasting?

Yes. Patients must take it in the morning on an empty stomach and avoid food or beverages other than water for **30 minutes after dosing**. It also requires an eight-hour fast before it can be taken.

### Q: Can it prevent heart attacks?

We don't know yet. While the drug lowers cholesterol, Merck is conducting ongoing trials to determine if it can reduce the risk of cardiovascular morbidity and mortality.

### Q: Is it better than statins?

It's different. Lipfendra works through a completely different mechanism than statins. It's not a replacement for statins—it's approved for use in patients already taking statins. But it can lower cholesterol far below what statins can achieve alone.

### Q: When will it be available?

The FDA approved Lipfendra on July 16, 2026. Merck says it will be available soon through the direct-to-patient TrumpRx program.

---

## Conclusion: A New Era in Cholesterol Management

The FDA approval of Lipfendra is a watershed moment in cardiovascular medicine. For the first time, patients have access to a once-daily pill that can lower "bad" cholesterol by up to 60%—matching the power of expensive injectable drugs at half the cost.

This is not just a new drug. It's a new paradigm.

Statins have been the backbone of cholesterol management for nearly 40 years. They're effective, but they have limits. For millions of patients who can't reach their LDL targets—or who can't tolerate statins at all—Lipfendra offers a completely new path forward.

The drug works through a different mechanism than statins. It's a pill, not an injection. It's half the price of injectable alternatives. And it's available through a direct-to-patient program that could make it accessible to millions.

Of course, there are caveats. The fasting requirements are strict. We don't yet know if the drug can actually prevent heart attacks and strokes. And the drug's effectiveness in "real-world" patients—outside the controlled environment of clinical trials—remains to be seen.

But for patients who have been waiting for a better option—who have struggled with statin side effects, who couldn't afford injectable PCSK9 inhibitors, or who simply couldn't get their cholesterol low enough—Lipfendra is a game-changer.

As cardiologist Eric Topol of the Scripps Research Institute put it: **"It is good to have an FDA-approved pill that works through the same known pathway and achieves LDL lowering comparable to the injectable PCSK9 drug inhibitors"**.

The era of the injectable PCSK9 inhibitor may be ending. The era of the oral PCSK9 inhibitor has just begun. And for millions of Americans at risk of heart disease, that's a development worth celebrating.

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute medical advice. Lipfendra (enlicitide) is a prescription medication that should only be taken under the supervision of a qualified healthcare provider. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Drug pricing, availability, and clinical trial data are subject to change. You should consult with your doctor or other qualified healthcare professional before starting, stopping, or changing any medication.

---

*Published: July 16, 2026*

-Read more --

**Tags:** Lipfendra, enlicitide, PCSK9 inhibitor, cholesterol medication, FDA approval, LDL cholesterol, Merck, heart disease, statins, hypercholesterolemia, familial hypercholesterolemia, cardiovascular disease, cholesterol pill, oral PCSK9, Repatha, Praluent, TrumpRx, Keytruda, cholesterol management, heart attack prevention

Apple vs. Nvidia: One Is Growing 10x Faster and Trades Cheaper. The Better AI Dividend Stock Is Clear.

 

Apple vs. Nvidia: One Is Growing 10x Faster and Trades Cheaper. The Better AI Dividend Stock Is Clear.

**Nvidia's revenue is growing at nearly five times Apple's rate, yet Apple trades at a higher P/E multiple. One of these tech titans offers superior growth, a cheaper valuation, and a more attractive dividend. The choice for long-term investors isn't as complicated as it seems.**

---

## Introduction: The Market Cap Race That Masks a Deeper Truth

The financial media is obsessed with one question: **Will Apple overtake Nvidia as the world's most valuable company?**

Apple is about 4% away from a $5 trillion market cap, and Nvidia currently holds the crown at $5.14 trillion. The gap has narrowed from $1.37 trillion in August 2025 to roughly $320 billion today. Apple shares have rallied 20% in 2026, hitting record after record.

But here's the problem with obsessing over market cap: **it tells you almost nothing about which stock is the better investment.**

When you look past the headline numbers, a clearer picture emerges. Nvidia is growing revenue at nearly five times Apple's rate, yet it trades at a cheaper valuation. And when it comes to dividends, one of these stocks offers a clear advantage that most investors are overlooking.

Let's break down the numbers.

---

## The Numbers That Matter: Growth, Valuation, and Dividends

### Revenue Growth: Nvidia Is in a Different League

| Metric | Apple | Nvidia |

|--------|-------|--------|

| **Latest Quarterly Revenue** | $111.2B | $81.6B |

| **Revenue Growth (YoY)** | ~17% | **85%** |

| **Data Center Revenue** | — | $75.25B (92% of total) |

The numbers are staggering. Nvidia's revenue grew 85% year-over-year to $81.6 billion, with data center revenue — the engine of the AI boom — reaching $75.25 billion. Apple's 17% growth is impressive for a company of its size, but it's less than one-fifth of Nvidia's growth rate.

Nvidia's gross margin sits around **75%**, while Apple's is roughly **48%**. The chipmaker is generating nearly $49 billion in free cash flow per quarter.

### Valuation: The Faster-Growing Stock Is Cheaper

| Metric | Apple | Nvidia |

|--------|-------|--------|

| **P/E Ratio** | ~37x | ~30x |

| **Market Cap** | ~$4.81T | ~$5.14T |

| **Forward P/E** | Premium | ~23x |

Here's the paradox: **Apple, the slower-growing company, trades at a higher multiple than Nvidia.** Apple commands a premium of roughly 37 times earnings, while Nvidia — growing at nearly five times the rate — trades at about 30 times earnings.

Some analysts believe Nvidia's forward P/E has compressed to as low as **23 times earnings**, despite 85% revenue growth. That's a remarkable disconnect: the company with dramatically superior growth is trading at a discount to its slower-growing peer.

### Dividends: One of These Stocks Is a Clear Winner

| Metric | Apple | Nvidia |

|--------|-------|--------|

| **Annual Dividend** | $1.08 | $0.28 |

| **Dividend Yield** | 0.33% | 0.14% |

| **Recent Increase** | 4% | — |

Both companies recently raised their dividends. Apple announced a 4% quarterly dividend increase to $0.27 per share. Nvidia's dividend stands at just $0.28 annually, yielding roughly 0.14%.

Neither stock is a "dividend play" in the traditional sense — yields are modest for both — but Apple offers nearly **2.5 times the dividend yield** of Nvidia. For investors seeking income alongside growth, Apple has a clear edge.

---

## Nvidia's Case: The AI Rocket Ship

Nvidia is arguably the biggest beneficiary of the AI revolution. The company's Blackwell architecture is in exceptionally strong demand, with adoption spanning hyperscalers, cloud providers, enterprises, AI startups, and sovereign customers. The company is expanding beyond GPUs with its Vera CPU platform, opening new growth opportunities in data center computing.

**Why Nvidia could be the better buy:**

- **85% revenue growth** with data center revenue nearly doubling year-over-year

- **75% gross margins** — among the highest in the industry

- **$75 billion+ in quarterly data center revenue** — the engine of the AI boom

- **~$49 billion in quarterly free cash flow**

- **Cheaper valuation** than Apple on a P/E basis

The risk? Nvidia's stock is at the mercy of AI sentiment, which has turned jumpy on worries about how much the AI build-out will cost. Investors are questioning whether the big cloud companies can keep funding an AI build-out this expensive. Nvidia doesn't report again until late August, so it has no company catalyst this month.

---

## Apple's Case: The Ecosystem Fortress

Apple's edge is a less cyclical business with a durable growth opportunity. The company is seen as a bigger AI beneficiary deeper into the AI boom's maturity, when on-device AI features become more important.

**Why Apple could be the better buy:**

- **2.5 billion active devices** — a massive platform for recurring revenue

- **Services revenue at an all-time high of ~$31 billion**

- **$147 billion in cash and marketable securities**

- **Less cyclical and volatile** than chipmakers

- **A catalyst on the calendar**: July 30 earnings report, with guidance for 14% to 17% revenue growth

Apple's premium valuation is understandable: its earnings are steadier than Nvidia's, its services arm throws off high-margin recurring revenue, and it carries far less cyclicality than a chipmaker sitting near what some investors fear is the top of a spending boom.

---

## The Verdict: Which Stock Is the Better AI Dividend Investment?

The answer depends on your investment goals:

**For pure growth investors:** Nvidia is the clear winner. The company is growing at 85%, dominating the AI infrastructure market, and trading at a cheaper valuation than its slower-growing peer. If the AI boom continues, Nvidia's earnings and stock price could continue to surge.

**For income-focused investors:** Apple offers nearly 2.5 times the dividend yield of Nvidia. Combined with its fortress balance sheet, massive installed base, and steady services revenue, Apple provides a more predictable income stream.

**For balanced portfolios:** Both stocks deserve consideration. As one analyst put it, investors should "buy Nvidia for AI-driven upside and Apple for durability". The two companies offer complementary strengths: Nvidia provides explosive growth, while Apple delivers stability and income.

---

## Frequently Asked Questions

### Q: Which company is growing faster?

A: Nvidia is growing significantly faster. Its latest quarterly revenue grew **85% year-over-year**, while Apple's grew about **17%**.

### Q: Which stock is cheaper?

A: Nvidia trades at about **30 times earnings** (or as low as 23 times forward earnings), while Apple trades at about **37 times earnings**. The faster-growing company is actually cheaper.

### Q: Which stock has the better dividend?

A: Apple has a significantly better dividend. Apple yields **0.33%** with a $1.08 annual dividend, while Nvidia yields just **0.14%** with a $0.28 annual dividend.

### Q: Is Apple about to overtake Nvidia in market cap?

A: Apple is about **4% away** from a $5 trillion market cap. The company needs to rise from roughly $327 to $340 per share to reach the milestone.

### Q: What are the risks for Nvidia?

A: The main risk is that AI spending slows. Investors are worried that cloud companies may not be able to sustain the expensive AI build-out. Nvidia is also exposed to chip stock volatility.

### Q: What are the risks for Apple?

A: Apple's main risk is slower growth. The company is growing at 17% — impressive for its size, but far below Nvidia's 85%. It also trades at a premium valuation.

---

## Conclusion: Growth, Value, or Income — The Choice Is Yours

The numbers tell a clear story:

**Nvidia offers superior growth (85% vs. 17%), a cheaper valuation (30x vs. 37x P/E), and dominates the AI infrastructure market.** It's the purest play on the AI revolution.

**Apple offers stability, a massive ecosystem of 2.5 billion devices, steady services revenue, and a significantly better dividend.** It's the safer, income-generating choice.

The market cap race between these two titans is fascinating, but it shouldn't drive your investment decision. One company is growing nearly five times faster and trades cheaper. The other offers a higher dividend, a fortress balance sheet, and less volatility.

The better AI dividend stock is clear — **but only once you know what you're looking for.**

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Market conditions, stock prices, and company performance are subject to rapid change. Past performance is not indicative of future results. All investments carry risk, including the potential loss of principal. You should consult with a qualified financial advisor before making any investment decisions. The views expressed in this article are those of the author and do not constitute a recommendation to buy or sell any security.

---

*Published: July 16, 2026*

--Read more-

**Tags:** Apple, AAPL, Nvidia, NVDA, AI stocks, dividend stocks, stock comparison, growth stocks, value investing, technology stocks, Magnificent Seven, AI infrastructure, semiconductor stocks, consumer tech, investment analysis, stock valuation, dividend yield, market cap, $5 trillion, tech investing